Skip to main content

Table 2 Correlation between LATS2 expression and clinicopathological features of gastric cancer

From: The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2

GroupsnLATS2 expressionP
HighLow
Gender0.165
 Male26786181 
 Female902268 
Age (year)0.797
 ≥ 6020260142 
 < 6015548107 
Tumor size0.572
 ≥ 525274178 
 < 51053471 
Borrmann’s types0.975
 Bor.I + II30921 
 Bor.III + IV32799228 
WHO’s histological types0.424
 Papillary adenocarcinoma633 
 Tubular adenocarcinoma
  Well differentiated1055 
  Moderately differentiated802357 
   Poorly differentiated21968151 
 Signet ring cell adenocarcinoma27621 
 Mucinous adenocarcinoma15312 
Lauren’s types0.211
 Intestinal962571 
 Diffuse18060120 
 Mixed812358 
Depth of invasion0.615
 T1 + 226917 
 T3 + 433199232 
Lymph node metastasis0.503
 N0782652 
 N1–327982197 
Distant metastasis0.130
 M0345102243 
 M11266 
TNM staging0.047
 I + II1003862 
 III + IV25770187 
  1. Significance of P < 0.05 is indicated in italic